Serotonin (5-HT) syndrome is a potentially fatal condition associated with various combinations of
serotonergic drugs.
Hyperthermia is the most serious symptom of this syndrome.
Hyperthermia in
5-HT syndrome is reportedly the result of activation of 5-HT(2A) receptors.
Mirtazapine is a novel
antidepressant and a potent 5-HT(2) receptor antagonistic. Although
mirtazapine has been reported to cause
5-HT syndrome, the pharmacological profile of
mirtazapine suggests that it improves
hyperthermia in
5-HT syndrome. In the present study, we evaluated whether
mirtazapine attenuates
hyperthermia in a rat model of
5-HT syndrome. This model was induced by administration of
tranylcypromine, a nonselective
monoamine oxidase inhibitor, and
fluoxetine, a
selective serotonin reuptake inhibitor. Upon injection of these two drugs, the rectal temperature of the rats increased to over 40 degrees C. Pre- and post-administration of
mirtazapine abolishes
hyperthermia in this model of
5-HT syndrome. Post-administration of
ritanserin, a
5-HT(2A) receptor antagonist, completely inhibited
hyperthermia and pre-administration of WAY100635, a
5-HT(1A) receptor antagonist, significantly attenuated the ability of
mirtazapine to abolish
hyperthermia. The results of the present study suggest that
mirtazapine inhibits
hyperthermia in an animal model of
5-HT syndrome by blocking the activation of 5-HT(2A) receptors, and that it partly inhibits
hyperthermia by activating the 5-HT(1A) receptors. The present study indicates that
mirtazapine is unlikely to cause
5-HT syndrome and may be a useful drug for treating this condition.